Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

• Conditions: Melanoma; Radiotherapy; Metastatic Disease

• Registration Number: NCT00406900
• Lead Sponsor: Ludwig-Maximilians - University of Munich

Brief Summary

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Detailed Description

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Study Timeline

• Study Start: 1999-01
• Study Completion: 2006-09
• Status Verified: 2006-11
• Study First Submitted: 2006-11-29
• Study First Submitted QC: 2006-11-29
• Study First Posted: 2006-12-04
• Last Update Submitted: 2006-12-05
• Last Update Posted: 2006-12-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 560

Inclusion Criteria

• uveal melanoma (With/without overt metastatic disease)

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Dept of Ophthalmology, University of Munich; 🇩🇪 Munich, Germany